UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Faldaprevir and Deleobuvir for HCV Genotype 1 Infection

The New England journal of medicine, 2013-08, Vol.369 (7), p.630-639

2013

Volltextzugriff (PDF)

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

Hepatology (Baltimore, Md.), 2013-06, Vol.57 (6), p.2143-2154

2013

Volltextzugriff (PDF)

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

Gastroenterology (New York, N.Y. 1943), 2011-12, Vol.141 (6), p.2047-2055

2011

Volltextzugriff (PDF)

Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: A prospective study

Gynecologic oncology, 2012-11, Vol.127 (2), p.332-337

2012

Volltextzugriff (PDF)

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment

PloS one, 2016-12, Vol.11 (12), p.e0168544

2016

Volltextzugriff (PDF)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir

PloS one, 2016-08, Vol.11 (8), p.e0160668

2016

Volltextzugriff (PDF)

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

Journal of hepatology, 2011-06, Vol.54 (6), p.1114-1122

2011

Volltextzugriff (PDF)

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection

PloS one, 2015-12, Vol.10 (12), p.e0144004

2015

Volltextzugriff (PDF)

Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir

Antimicrobial Agents and Chemotherapy, 2014-02, Vol.58 (2), p.698-705

2014

Volltextzugriff (PDF)

Drug-Induced Liver Injury Associated with the Use of Nonnucleoside Reverse-Transcriptase Inhibitors

Clinical infectious diseases, 2004-03, Vol.38 (Supplement-2), p.S80-S89

2004

Volltextzugriff (PDF)

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Hepatology (Baltimore, Md.), 2013-06, Vol.57 (6), p.2155-2163

2013

Volltextzugriff (PDF)

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients

The Journal of pharmacology and experimental therapeutics, 2014-11, Vol.351 (2), p.403-412

2014

Volltextzugriff (PDF)

Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C

Antimicrobial Agents and Chemotherapy, 2013-10, Vol.57 (10), p.4727-4735

2013

Volltextzugriff (PDF)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients

Antimicrobial agents and chemotherapy, 2014-06, Vol.58 (6), p.3429-3436

2014

Volltextzugriff (PDF)

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

Journal of hepatology, 2015-06, Vol.62 (6), p.1246-1255

2015

Volltextzugriff (PDF)

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

Journal of acquired immune deficiency syndromes (1999), 2003-09, Vol.34 Suppl 1, p.S21-S33

2003

Volltextzugriff (PDF)

Su1025 Interferon-Stimulated Gene Expression Is Associated With Treatment Response to Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Patients With Chronic HCV Genotype-1 Infection

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-965-S-966

2014

Volltextzugriff (PDF)

Safety and efficacy of faldaprevir in combination with pegylated interferon α‐2b and ribavirin in Japanese patients with genotype‐1 chronic hepatitis C virus infection

Hepatology research, 2017-03, Vol.47 (3), p.E142-E151

2017

Volltextzugriff (PDF)

Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study

Liver international, 2015-02, Vol.35 (2), p.417-421

2015

Volltextzugriff (PDF)

Safety and efficacy of faldaprevir in combination with pegylated interferon [alpha]-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection

Hepatology research, 2017-03, Vol.47 (3), p.E142

2017

Volltextzugriff (PDF)

Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV

AIDS (London), 2015-03, Vol.29 (5), p.571-581

2015

Volltextzugriff (PDF)

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis

Antimicrobial agents and chemotherapy, 2015-02, Vol.59 (2), p.1282-1291

2015

Volltextzugriff (PDF)

Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

Antiviral therapy, 2013-01, Vol.18 (8), p.1015-1019

2013

Volltextzugriff (PDF)

Hepatic profile analyses of tipranavir in Phase II and III clinical trials

BMC infectious diseases, 2009-12, Vol.9 (1), p.203-203, Article 203

2009

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(155)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(109)
Life Sciences & Biomedicine
(97)
Humans
(87)
Female
(54)
Biological And Medical Sciences
(49)
Male
(47)
Middle Aged
(38)
Medical Sciences
(37)
Adult
(32)
Animals
(28)
Aged
(19)
Gastroenterology And Hepatology
(17)
Hepatitis C, Chronic - Drug Therapy
(16)
Antiviral Agents - Therapeutic Use
(15)
Fundamental And Applied Biological Sciences. Psychology
(15)
Hepacivirus - Drug Effects
(15)
Infectious Diseases
(15)
Radiology, Nuclear Medicine & Medical Imaging
(15)
Hepacivirus - Genetics
(14)
Mice
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Faldaprevir and Deleobuvir for HCV Genotype 1 Infection

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: A prospective study

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection

Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir

Drug-Induced Liver Injury Associated with the Use of Nonnucleoside Reverse-Transcriptase Inhibitors

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients

Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

Su1025 Interferon-Stimulated Gene Expression Is Associated With Treatment Response to Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Patients With Chronic HCV Genotype-1 Infection

Safety and efficacy of faldaprevir in combination with pegylated interferon α‐2b and ribavirin in Japanese patients with genotype‐1 chronic hepatitis C virus infection

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin

Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study

Safety and efficacy of faldaprevir in combination with pegylated interferon [alpha]-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection

Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis

Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

Hepatic profile analyses of tipranavir in Phase II and III clinical trials

Suchergebnisse filtern